Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of PF-06863135 monotherapy in refractory multiple myeloma
2020-004533-21Phase 2Active
- Sponsor
- Pfizer
- Start
- Feb 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of elranatamab in multiple myeloma (MM) (2 cohorts), sponsored by Pfizer. Primary endpoint: ORR by BICR per IMWG. Started Feb 2021; status: active.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2020-004533-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004533-21.